Judge approves $120m Momenta and Sandoz settlement
06-01-2020
Momenta to pay $35m to end enoxaparin class-action suit
12-12-2019
designer491 / Shutterstock.com
Sandoz and Momenta have agreed to pay $120 million to bring an antitrust class action over blockbuster blood clot drug enoxaparin to an end.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Momenta Pharmaceuticals, Sandoz, Sanofi, enoxaparin, blood clots, generics, antitrust, competition, Nashville General Hospital, Lieff Cabraser
